Atrial Fibrillation (AF) trials recruiting in New York

All Atrial Fibrillation (AF) trials nationally

Cities in New York

Recruiting trials in New York

• Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
  NCT06935591 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years and older · Sex: All (male and female) · New York: Valhalla
• Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
  NCT07298473 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: New Hyde Park, New York, The Bronx
• Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
  NCT06957366 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
  NCT06844227 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · New York: Great Neck
• Prospective Remapping With Concomitant Left Atrial Appendage Occlusion to Ensure Durable Electroporation Study
  NCT07620262 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Bay Shore
• Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
  NCT07626411 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Staten Island
• Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
  NCT07430956 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Staten Island
• Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
  NCT05712200 · Phase: Phase 3 · Ages: 65 Years and older · Sex: All (male and female) · New York: Albany, Brooklyn, Hauppauge, Middletown